SCHEMBL12430899

SCHEMBL12430899

CCS(=O)(=O)Nc1ccc(Oc2nc(Nc3cc(C)[nH]n3)cc(-c3ccccc3)n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 4/20 0.49
PIK3C3 Q8NEB9 6/20 0.48
AURKA O14965 3/20 0.47
EGFR P00533 5/20 0.47
GSK3B P49841 3/20 0.46
SRC P12931 2/20 0.46
ALDH1A1 P00352 1/20 0.45
THRB P10828 1/20 0.45
HPGD P15428 1/20 0.45
GSK3A P49840 1/20 0.44
ITK Q08881 1/20 0.43
GRIN1 Q05586 1/20 0.42
GRIN2B Q13224 1/20 0.42
TBK1 Q9UHD2 1/20 0.42
IGF1R P08069 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12430897 0.94 AURKB (0.47) AURKBPIK3C3AURKAEGFRGSK3B
SCHEMBL12430896 0.84 AURKB (0.69) AURKBPIK3C3AURKAEGFRGSK3B
SCHEMBL12430887 0.83 AURKA (0.68) AURKBPIK3C3AURKAEGFRGSK3B
SCHEMBL12430815 0.81 AURKB (0.73) AURKBAURKAGSK3BSRC
SCHEMBL12430890 0.81 AURKA (0.51) AURKBPIK3C3AURKAEGFRGSK3B
SCHEMBL12430913 0.81 AURKB (0.58) AURKBPIK3C3AURKAEGFRGSK3B
SCHEMBL12430898 0.79 AURKB (0.54) AURKBAURKAEGFRGSK3BSRC
SCHEMBL12510643 0.76 AURKB (0.58) AURKBPIK3C3AURKAEGFRGSK3B
SCHEMBL13054754 0.76 AURKA (0.46) AURKBPIK3C3AURKAEGFRGSK3B
SCHEMBL12430810 0.76 AURKB (0.70) AURKBAURKAGSK3BSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA AURKB 7/4885PIK3C3 322/4885AURKA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.